Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2006

View Archived Issues

Bolder BioTechnology awarded SBIR grant to study long-acting VEGF inhibitor

Third phase III trial of Corlux in psychotic major depression completes enrollment

Yaupon Therapeutics closes financing in support of pipeline progression

Sanofi-aventis, Innogenetics and Inserm collaborate on Alzheimer's disease

Phase I and preclinical data on kinesin-like spindle protein inhibitors presented

Preliminary phase I data reveal tolerability of XL-820 in cancer patients

Studies reveal tocilizumab efficacy in arthritis

Ocrelizumab/methotrexate combination active in rheumatoid arthritis patients

Responses seen with TRU-015 in rheumatoid arthritis study

AME-527 shows promise in rheumatoid arthritis

Stem cell vaccine prevents lung cancer in rodents

New trial investigates PXD-101 for ovarian cancer

Cannasat and IntelGenx to codevelop novel cannabinoid-based products

Gilead Sciences completes tender offer for Myogen

IND amendment for AVR-118 to include topical and intralesional therapy

Soliris BLA accepted for priority review

Samaritan to acquire Metastatin Pharmaceuticals

Helix completes phase II study of topical interferon alpha-2b in LSIL

FDA lifts clinical hold on epratuzumab lupus trials

IND filed in India for ZYO-1

Positive preclinical and clinical results for CD34 stem cell therapy in coronary artery disease

Takeda looks back on active first half

Cardioprotective effects of chocolate consumption shown in healthy subjects and transplant patients

Swiss approvable letter for IDEA-033 to treat signs and symptoms of osteoarthritis

Salvat establishes U.S. subsidiary, plans launch of Cetraxal Otico

Tamoxifen/fenretinide combo does not result in synergistic activity in breast cancer

Frondanol-A5: A compound from sea cucumber with nutrapreventive/therapeutic properties

Recent patents impart new therapeutic agents for cancer

Recent patents report novel analgesic agents

Emerging companies showcased at BIO-Europe 2006: Noxxon Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...